Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -66.37% | -61.19% | -53.52% | -51.32% | 142.36% |
| Total Depreciation and Amortization | 24.91% | 9.71% | -0.19% | -3.17% | -2.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.07% | -31.38% | -33.60% | -36.88% | 42.64% |
| Change in Net Operating Assets | 93.90% | 102.72% | 91.74% | 91.29% | -757.56% |
| Cash from Operations | -2.90% | 9.60% | 5.74% | 11.78% | 4.48% |
| Capital Expenditure | 4.72% | 8.00% | 9.03% | 1.63% | 1.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -23,550.59% | -66,690.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | -6.82% | -13.18% | -215.38% | -10.61% | -60.00% |
| Cash from Investing | -838.74% | -790.41% | -834.79% | -3.59% | -3.44% |
| Total Debt Issued | 496,325.00% | 398,380.00% | 8,781.70% | -97.76% | -98.36% |
| Total Debt Repaid | -95.56% | -108.24% | -19.64% | -113.03% | -95.21% |
| Issuance of Common Stock | -46.15% | -56.04% | -46.04% | 50.00% | 52.38% |
| Repurchase of Common Stock | -69.76% | -35.50% | 41.22% | 31.04% | 26.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -6.92% | -7.25% | -7.25% | -7.30% | -7.38% |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Financing | 247.54% | 261.45% | 307.85% | -16.75% | -21.05% |
| Foreign Exchange rate Adjustments | 33.33% | -182.14% | 166.67% | 173.96% | -250.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7,259.57% | -5,030.56% | 9.27% | 25.83% | -105.54% |